Aims: The aims of this study were to 1) determine if vacuum assisted closure therapy (VAC) helps assist closure in diabetic foot ulcers and wounds secondary to peripheral vascular disease, 2) if it helps debride wounds and 3) if it prevents the need for further surgery

Materials and Methods: 15 patients were reviewed, average age 49.3yrs at an average of 6.3 months (1–18months). Ten patients had diabetes (8 IDDM) with 5 patients having grade 3 ulcers (Wagner-Meggitt). All wounds were surgically debrided prior to the application of the VAC therapy. The VAC therapy was applied according to the manufacturers instrucrtions. The main outcome measures were 1) time to satisfactory wound closure 2) change in the wound surface area and 3) need for further surgery

Results: Satisfactory healing was achieved in 11 patients (73.3%). 10 were diabetic, 5 patients had peripheral vascular disease and 5 patients had both. The time to satisfactory healing was 2.5 months, average 1–6 months. The average size of the wound ulcer was 7.41cm2 (2–10cm2) prior to treatment and 1.58cm2 (0–2cm2) following treatment in an average of 2.5 months. VAC therapy helped debride all non healing wounds following surgical debridement. In 10 patients, the need for further radical surgery, namely amputation, was avoided.

Conclusion: VAC therapy is a useful adjunct to the standard treatment of chronic wound /ulcers in patients with diabetes with or without periphearl vascular disease. Its use in foot and ankle surgery leads to a quick wound closure and in some cases avoids the need for further surgery with a potential for limb salvage.

Aims

The aims of this study were to determine if vacuum assisted closure (VAC) therapy affords quicker wound closure in diabetic and ischaemic wounds or ulcers than standard treatment, if it helps debride wounds and if it prevents the need for further surgery.

Materials and methods

We retrospectively reviewed 12 patients, average aged 52.1 yrs (22 to 67) at an average of 6.3 months (1 to12 months). Seven had diabetes and three had chronic osteomyelitis. All wounds or ulcers were surgically debrided prior to application of the VAC therapy. The VAC therapy was applied according to the manufacturers instructions. The main outcome measures were the time to satisfactory healing and the change in the wound surface area.

Results

Satisfactory healing was achieved in six patients (50%), seven were diabetic and one patient had peripheral vascular disease. The average time to satisfactory healing was 2.5 months, (1 to 6 months). The average size of the wound /ulcer was 7.41 cm2 prior to treatment and 1.58 cm2 following treatment for an average 2.5 months in those in whom the wound/ulcer was still present. VAC therapy helped debride all wounds which remained sloughy following surgical debridement. In 8 patients the need for further surgery, such as soft tissue flaps or more radical surgery was avoided.

Conclusion

VAC therapy is a useful adjunct to the standard treatment of chronic wound /ulcers in patients with diabetes or peripheral vascular disease. Its use in foot and ankle surgery leads to a quicker wound closure and in some cases, avoids the need for further surgery. There are significant economic cost savings with its use in foot and ankle surgery.